200,000+ products from a single source!
sales@angenechem.com
158382-37-7 | Glycine, L-γ-glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)-
CAS No: 158382-37-7 Catalog No: AG001Q5I MDL No:
Product Description
Catalog Number:
AG001Q5I
Chemical Name:
Glycine, L-γ-glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)-
CAS Number:
158382-37-7
Molecular Formula:
C26H40Cl4N5O10PS
Molecular Weight:
787.4741
IUPAC Name:
(2S)-2-amino-5-[[(2R)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(R)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid
InChI:
InChI=1S/C26H40Cl4N5O10PS/c27-8-12-33(13-9-28)46(42,34(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32)24(37)35(22(36)7-6-20(31)25(38)39)23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31-32H2,(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1
InChI Key:
VESKBLGTHHPZJF-QNWVGRARSA-N
SMILES:
ClCCN(P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@@H](C(=O)NC(c1ccccc1)C(=O)O)NC(=O)CC[C@@H](C(=O)O)N)CCCl
Properties
Complexity:
1150
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
3
Defined Bond Stereocenter Count:
0
Exact Mass:
787.096g/mol
Formal Charge:
0
Heavy Atom Count:
47
Hydrogen Bond Acceptor Count:
14
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
787.465g/mol
Monoisotopic Mass:
785.099g/mol
Rotatable Bond Count:
24
Topological Polar Surface Area:
239A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-4.3
Literature
| Title | Journal |
|---|---|
| Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100701 |
| Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. | Journal of hematology & oncology 20100101 |
| Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091101 |
| Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Novel cytotoxic agents for non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901 |
| New developments in chemotherapy for advanced non-small cell lung cancer. | Current opinion in oncology 20060301 |
| TLK-286: a novel glutathione S-transferase-activated prodrug. | Expert opinion on investigational drugs 20050801 |
| Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. | Methods in enzymology 20050101 |
| TLK-286. | IDrugs : the investigational drugs journal 20040801 |
| Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040601 |
| Current data and ongoing trials in patients with recurrent non-small-cell lung cancer. | Clinical lung cancer 20040501 |
| TLK 286. | Drugs in R&D 20040101 |
| Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030501 |
| Sensitivity and fidelity of DNA microarray improved with integration of Amplified Differential Gene Expression (ADGE). | BMC genomics 20030101 |
| Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. | Molecular cancer therapeutics 20021001 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.